12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SNS01-T: Phase Ib/IIa ongoing

Senesco said a data review committee recommended continuation to the fourth cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial of IV SNS01-T given twice weekly for 6 weeks after reviewing safety data from the third cohort, which showed the 0.2 mg/kg dose was well tolerated. The fourth cohort will enroll...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >